Peptris Technologies out-licenses AI-discovered drug candidate to Revio Therapeutics
Under the agreement, Revio Therapeutics will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Duchenne muscular dystrophy
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
Novel therapies and regulatory shifts drive growth in the Duchenne muscular dystrophy market, with exon-skipping therapies leading…
FDA expands approval of gene therapy for patients with Duchenne Muscular Dystrophy
Elevidys now approved for both ambulatory and non-ambulatory patients aged four and older
Pfizer investigational gene therapy for DMD fails in Phase 3 study
The overall safety profile of fordadistrogene movaparvovec in the CIFFREO trial was manageable, with mostly mild to moderate…
Givinostat from Italfarmaco gets FDA rare pediatric disease designation in duchenne muscular…
Announces completed enrollment in EPIDYS Phase 3 trial
US FDA approves Viltepso injection for treatment of Duchenne muscular dystrophy mutation
The approval was granted to NS Pharma
FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy…
It is estimated that about 8 percent of patients with DMD have mutation of the dystrophin gene that is amenable to exon 53…